Document Detail


Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis.
MedLine Citation:
PMID:  20581020     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We conducted an open-labeled, prospective study to determine the efficacy and safety of tacrolimus as an alternative therapeutic option for those patients with refractory lupus nephritis. The study population comprised one male and eight female patients with diffuse proliferative lupus nephritis. All patients had failed to respond to sufficient intravenous cyclophosphamide therapy with proteinuria of >or=1 g/day and active urinary sediments. Tacrolimus (0.1 mg/kg/day) was administered for 1 year with adjusting drug level (4-10 microg/l). The mean serum creatinine level and spot urine protein creatinine ratio (UPCR) at baseline were 1.39 mg/dl and 2.27, respectively. After the treatment, proteinuria reduced significantly from median UPCR value of 2.19 (range, 1.19-3.34) to 0.44 (range, 0.12-2.13) (p < 0.05). Seven (78%) of the nine patients showed a complete clinical response, which was defined as stabilization in the disease-activity markers and serum creatinine level with reduction of >or=50% in UPCR; two patients showed complete remission with UPCR <0.2. One patient showed treatment failure because of the disease progression. No serious adverse effects were observed during the study. This study demonstrates that tacrolimus can show a significant therapeutic response in cases that are refractory to the standard regimen for diffuse proliferative lupus nephritis.
Authors:
T Lee; K-H Oh; K W Joo; Y S Kim; C Ahn; J S Han; S Kim; H J Chin
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Lupus     Volume:  19     ISSN:  1477-0962     ISO Abbreviation:  Lupus     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-28     Completed Date:  2010-11-04     Revised Date:  2011-03-11    
Medline Journal Info:
Nlm Unique ID:  9204265     Medline TA:  Lupus     Country:  England    
Other Details:
Languages:  eng     Pagination:  974-80     Citation Subset:  IM    
Affiliation:
Department of Biomedical Sciences, Seoul National University Graduate School, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cyclophosphamide / therapeutic use
Disease Progression
Female
Humans
Immunosuppressive Agents / therapeutic use*
Lupus Nephritis / drug therapy*,  physiopathology
Male
Middle Aged
Prospective Studies
Tacrolimus / therapeutic use*
Treatment Failure
Treatment Outcome
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proli...
Next Document:  Chemosis as a presenting symptom of systemic lupus erythematosus.